H_IL17A Reporter 293 Cell Line
Cat. No.
GM-C06721
Size
1 vial
Quote
Description
Data Display
Specifications
Materials
Cell Culture
Related products
Description
IL-17 is a pro-inflammatory cytokine mainly produced by Th17 cells. It is crucial for immune defense against bacterial and fungal infections and is linked to autoimmune diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis. The IL-17 family includes several members, with IL-17A and IL-17F being the most studied.

The IL-17 signaling pathway starts when IL-17 binds to its receptor, IL-17R, composed of IL-17RA and IL-17RC subunits. This binding activates downstream molecules like ACT1, which then activate the NF-κB and MAPK pathways. These pathways increase the expression of pro-inflammatory cytokines and chemokines, enhancing inflammatory responses. The pathway also influences immune responses by affecting cell survival, proliferation, and differentiation.

H_IL17A Reporter 293 Cell Line is a clonal stable cell line constructed using lentiviral technology, constitutive expression of the IL-17RA, IL-17RC and some adapter membrane molecules, along with signal-dependent expression of a luciferase reporter gene. When IL-17A/F binds to IL-17R, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can inhibit this signal transmission. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to IL-17.
IL-17 is a pro-inflammatory cytokine mainly produced by Th17 cells. It is crucial for immune defense against bacterial and fungal infections and is linked to autoimmune diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis. The IL-17 family includes several members, with IL-17A and IL-17F being the most studied.

The IL-17 signaling pathway starts when IL-17 binds to its receptor, IL-17R, composed of IL-17RA and IL-17RC subunits. This binding activates downstream molecules like ACT1, which then activate the NF-κB and MAPK pathways. These pathways increase the expression of pro-inflammatory cytokines and chemokines, enhancing inflammatory responses. The pathway also influences immune responses by affecting cell survival, proliferation, and differentiation.

H_IL17A Reporter 293 Cell Line is a clonal stable cell line constructed using lentiviral technology, constitutive expression of the IL-17RA, IL-17RC and some adapter membrane molecules, along with signal-dependent expression of a luciferase reporter gene. When IL-17A/F binds to IL-17R, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can inhibit this signal transmission. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to IL-17.
Data Display
Signaling Pathway
Response to Recombinant Human IL-17A (C-6His). The H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Recombinant Human IL-17A (C-6His) (Novoprotein/C774) in assay buffer (EMEM + 1% FBS + 1% P.S) for 7 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [11.2]. Data are shown by drug mass concentration.
Applications
Response to Anti-IL-17A hIgG1 Antibody(Secukinumab). Serial dilutions of Anti-IL-17A hIgG1 Antibody(Secukinumab) (Cat. GM-27267AB) was incubated with 0.832 ng/well of Recombinant Human IL-17A (C-6His) (Novoprotein/C774) for 1 hour in assay buffer (EMEM + 1% FBS + 1% P.S). After pre-incubation, add the mixture to the H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a density of 1.5E4 cells/well in a 96-well format, and incubate for 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [4.0]. Data are shown by drug mass concentration.
Stability
The passage stability of response to Recombinant Human IL-17A (C-6His). The passage 5, 10, 15, 20 and 25 of H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a concentration of 1.5E4 cells/well (96-well format) were stimulated with serial dilutions of Recombinant Human IL-17A (C-6His) (Novoprotein/C774) in assay buffer (EMEM + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). Data are shown by drug mass concentration.
Specificity
Response to human IL-17F protein and human IL-17E protein. The H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a concentration of 1.5E4 cells/well (96-well format) was separately stimulated with serial dilutions of Recombinant Human IL-17F (C-6His) (Novoprotein/CA22) and Recombinant Human IL-25(IL-17E) (C-6His) (Novoprotein/C792) in assay buffer (EMEM(ATCC) + 1% FBS + 1% P.S) for 16 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [22.1] and [12.9], respectively. Data are shown by drug mass concentration.
Expression
H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) was determined by flow cytometry using Anti-IL17RA hIgG2 Antibody(brodalumab) (Cat. GM-47619AB).
Specifications
Cat. No GM-C06721
Product H_IL17A Reporter 293 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium EMEM+10% FBS+1% P.S
Growth medium EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin
Note  
Freezing Medium 90% FBS+10% DMSO
Growth properties Adherent
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Cat. No GM-C06721
Product H_IL17A Reporter 293 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium EMEM+10% FBS+1% P.S
Growth medium EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin
Note  
Freezing Medium 90% FBS+10% DMSO
Growth properties Adherent
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Materials
Reagent Ordering Information
EMEM ATCC/30-2003
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Blasticidin Genomeditech/GM-040404
Bleomycin Genomeditech/GM-040407
Hygromycin Genomeditech/GM-040403
Puromycin Genomeditech/GM-040401
Recombinant Human IL-17A (C-6His) Novoprotein/C774
Recombinant Human IL-17F (C-6His) Novoprotein/CA22
Recombinant Human IL-25 (C-6His) Novoprotein/C792
Anti-IL-17A hIgG1 Antibody(Secukinumab) Genomeditech/GM-27267AB
Anti-IL17RA hIgG2 Antibody(brodalumab) Genomeditech/GM-47619AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit Genomeditech/GM-040513
Reagent Ordering Information
EMEM ATCC/30-2003
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Blasticidin Genomeditech/GM-040404
Bleomycin Genomeditech/GM-040407
Hygromycin Genomeditech/GM-040403
Puromycin Genomeditech/GM-040401
Recombinant Human IL-17A (C-6His) Novoprotein/C774
Recombinant Human IL-17F (C-6His) Novoprotein/CA22
Recombinant Human IL-25 (C-6His) Novoprotein/C792
Anti-IL-17A hIgG1 Antibody(Secukinumab) Genomeditech/GM-27267AB
Anti-IL17RA hIgG2 Antibody(brodalumab) Genomeditech/GM-47619AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit Genomeditech/GM-040513
Cell Culture

Cell Recovery

Recovery Medium: EMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a)          Remove and discard culture medium.

b)         Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.

c)          Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).

d)         Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

e)          Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.

f)          After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.

g)         Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a)          Upon initial revival, a higher number of dead cells and poor adherence are observed, which is normal. Adherence typically recovers within 2 - 3 days. After 2 - 3 passages, the proportion of adherent cells increases, and the cells begin to spread normally.

b)         After each passage, there may be 5 - 10% dead cells; however, as the number of passages increases, the recovery rate accelerates, the proportion of dead cells decreases, and the cell growth rate stabilizes.

c)          It is recommended to retain cell images after revival and during each observation to assist in assessing cell status. In case of abnormalities, promptly communicate with Genomeditech sales.

Cell Recovery

Recovery Medium: EMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a)          Remove and discard culture medium.

b)         Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.

c)          Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).

d)         Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

e)          Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.

f)          After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.

g)         Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a)          Upon initial revival, a higher number of dead cells and poor adherence are observed, which is normal. Adherence typically recovers within 2 - 3 days. After 2 - 3 passages, the proportion of adherent cells increases, and the cells begin to spread normally.

b)         After each passage, there may be 5 - 10% dead cells; however, as the number of passages increases, the recovery rate accelerates, the proportion of dead cells decreases, and the cell growth rate stabilizes.

c)          It is recommended to retain cell images after revival and during each observation to assist in assessing cell status. In case of abnormalities, promptly communicate with Genomeditech sales.

Related products
IL-17
H_IL17A Reporter 293 DDX35TM Cell Line Membrane Bound H_IL17A CHO-K1 Cell Line
Anti-IL-17A hIgG1 Antibody(Secukinumab) Anti-IL17A hIgG1 Reference Antibody (Secubio) Anti-IL17A hIgG4 Reference Antibody (Ixebio)
Anti-IL17A×IL17F hIgG1 Bispecific Antibody(Bimebio) Anti-IL17A×IL17F hIgG1 Bispecific Antibody(VH1-1-VL5)
Biotinylated Human IL-17A Protein; His-Avi Tag Biotinylated Human IL-17RA Protein; His-Avi Tag Cynomolgus IL-17A Protein; His Tag
Cynomolgus IL-17F Protein; His Tag Human IL-17A Protein; hFc Tag Human IL-17A Protein; His Tag
Human IL-17E Protein; His Tag Human IL-17F Protein; His Tag  
IL-23
H_IL-23 Reporter 293 Cell Line H_IL-23 Reporter 293 DDX35TM Cell Line Cynomolgus_IL-23R HEK-293 Cell Line
H_IL-23R HEK-293 Cell Line H_IL-23R IL12RB1 HEK-293 Cell Line Membrane bound H_IL-23 CHO-K1 Cell Line
Anti-IL23A hIgG1 Reference Antibody (Gusebio) Anti-IL23A hIgG1 Reference Antibody (Risbio) Anti-IL-23R hIgG1 Antibody(5D4)
Biotinylated Human IL-23A&IL-12B Heterodimer Protein; His-Avi Tag Cynomolgus IL-23A & Human IL-12B Heterodimer Protein; His Tag Cynomolgus IL-23A & Mouse IL-12B Heterodimer Protein; His Tag
Cynomolgus IL-23R Protein; hFc Tag Human IL-23A & Mouse IL-12B Heterodimer Protein; His Tag Human IL-23A&IL-12B Heterodimer Protein; His Tag
Human IL-23R Protein; hFc Tag Human IL-23R Protein; His Tag Mouse IL-23A&IL-12B Heterodimer Protein; His Tag
TNF:TNFR2:TNFR1
H_TNFR2 Null Reporter Cell Line H_TNFR2 Reporter Jurkat Cell Line H_TNFR2 Reporter V2 Cell Line
Cynomolgus_TNFRSF1B(TNFR2) CHO-K1 Cell Line H_TNFRSF1B(TNFR2) CHO-K1 Cell Line H_TNFRSF1B(TNFR2) HEK-293 Cell Line
Membrane Bound H_TNFα CHO-K1 Cell Line Membrane Bound H_TNFα(cleavage-resistant) CHO-K1 Cell Line
Anti-H_TNFRSF1B(TNFR2) hIgG1 Antibody(UC2.3.8) Anti-TNFR1 hIgG1 Antibody(Atrosab) Anti-TNF-α hIgG1 Reference Antibody (Adabio)
Cynomolgus TNFR2 Protein; His Tag Human TNF alpha Protein; hFc Tag Human TNF alpha Protein; His Tag
Human TNFR1 Protein; hFc Tag Human TNFR1 Protein; His Tag Human TNFR2 Protein; hFc Tag
Human TNFR2 Protein; His Tag    
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
H_IL17A Reporter 293 Cell Line
Cat. No.
GM-C06721
Size
1 vial
Quote
Description
Data Display
Specifications
Materials
Cell Culture
Related products
Description
IL-17 is a pro-inflammatory cytokine mainly produced by Th17 cells. It is crucial for immune defense against bacterial and fungal infections and is linked to autoimmune diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis. The IL-17 family includes several members, with IL-17A and IL-17F being the most studied.

The IL-17 signaling pathway starts when IL-17 binds to its receptor, IL-17R, composed of IL-17RA and IL-17RC subunits. This binding activates downstream molecules like ACT1, which then activate the NF-κB and MAPK pathways. These pathways increase the expression of pro-inflammatory cytokines and chemokines, enhancing inflammatory responses. The pathway also influences immune responses by affecting cell survival, proliferation, and differentiation.

H_IL17A Reporter 293 Cell Line is a clonal stable cell line constructed using lentiviral technology, constitutive expression of the IL-17RA, IL-17RC and some adapter membrane molecules, along with signal-dependent expression of a luciferase reporter gene. When IL-17A/F binds to IL-17R, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can inhibit this signal transmission. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to IL-17.

IL-17 is a pro-inflammatory cytokine mainly produced by Th17 cells. It is crucial for immune defense against bacterial and fungal infections and is linked to autoimmune diseases like rheumatoid arthritis, psoriasis, and multiple sclerosis. The IL-17 family includes several members, with IL-17A and IL-17F being the most studied.

The IL-17 signaling pathway starts when IL-17 binds to its receptor, IL-17R, composed of IL-17RA and IL-17RC subunits. This binding activates downstream molecules like ACT1, which then activate the NF-κB and MAPK pathways. These pathways increase the expression of pro-inflammatory cytokines and chemokines, enhancing inflammatory responses. The pathway also influences immune responses by affecting cell survival, proliferation, and differentiation.

H_IL17A Reporter 293 Cell Line is a clonal stable cell line constructed using lentiviral technology, constitutive expression of the IL-17RA, IL-17RC and some adapter membrane molecules, along with signal-dependent expression of a luciferase reporter gene. When IL-17A/F binds to IL-17R, it activates downstream signaling pathways, leading to the expression of luciferase. Blockade antibodies can inhibit this signal transmission. The luciferase activity measurement indicates the activation level of the signaling pathway and can thus be used to evaluate the in vitro effects of drugs related to IL-17.

Data Display
Signaling Pathway
Response to Recombinant Human IL-17A (C-6His). The H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a concentration of 1.5E4 cells/well (96-well format) was stimulated with serial dilutions of Recombinant Human IL-17A (C-6His) (Novoprotein/C774) in assay buffer (EMEM + 1% FBS + 1% P.S) for 7 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [11.2]. Data are shown by drug mass concentration.
Applications
Response to Anti-IL-17A hIgG1 Antibody(Secukinumab). Serial dilutions of Anti-IL-17A hIgG1 Antibody(Secukinumab) (Cat. GM-27267AB) was incubated with 0.832 ng/well of Recombinant Human IL-17A (C-6His) (Novoprotein/C774) for 1 hour in assay buffer (EMEM + 1% FBS + 1% P.S). After pre-incubation, add the mixture to the H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a density of 1.5E4 cells/well in a 96-well format, and incubate for 6 hours. Firefly luciferase activity is then measured using the Luciferase Reporter Assay Kit (Genomeditech). The results indicated maximum blocking folds of approximately [4.0]. Data are shown by drug mass concentration.
Stability
The passage stability of response to Recombinant Human IL-17A (C-6His). The passage 5, 10, 15, 20 and 25 of H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a concentration of 1.5E4 cells/well (96-well format) were stimulated with serial dilutions of Recombinant Human IL-17A (C-6His) (Novoprotein/C774) in assay buffer (EMEM + 1% FBS + 1% P.S) for 6 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). Data are shown by drug mass concentration.
Specificity
Response to human IL-17F protein and human IL-17E protein. The H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) at a concentration of 1.5E4 cells/well (96-well format) was separately stimulated with serial dilutions of Recombinant Human IL-17F (C-6His) (Novoprotein/CA22) and Recombinant Human IL-25(IL-17E) (C-6His) (Novoprotein/C792) in assay buffer (EMEM(ATCC) + 1% FBS + 1% P.S) for 16 hours. The firefly luciferase activity was measured using the Luciferase Reporter Assay Kit (Genomeditech). The maximum induction fold was approximately [22.1] and [12.9], respectively. Data are shown by drug mass concentration.
Expression
H_IL17A Reporter 293 Cell Line (Cat. GM-C06721) was determined by flow cytometry using Anti-IL17RA hIgG2 Antibody(brodalumab) (Cat. GM-47619AB).
Specifications
Cat. No GM-C06721
Product H_IL17A Reporter 293 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium EMEM+10% FBS+1% P.S
Growth medium EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin
Note  
Freezing Medium 90% FBS+10% DMSO
Growth properties Adherent
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Cat. No GM-C06721
Product H_IL17A Reporter 293 Cell Line
Product Format 1 vial of frozen cells
Quantity 5E6 Cells per vial,1 mL
Storage Conditions Liquid nitrogen immediately upon receipt
Recovery Medium EMEM+10% FBS+1% P.S
Growth medium EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin
Note  
Freezing Medium 90% FBS+10% DMSO
Growth properties Adherent
Growth Conditions 37°C, 5% CO₂
Safety considerations Biosafety Level 2
Mycoplasma Testing The cell line has been screened to confirm the absence of Mycoplasma species.
Materials
Reagent Ordering Information
EMEM ATCC/30-2003
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Blasticidin Genomeditech/GM-040404
Bleomycin Genomeditech/GM-040407
Hygromycin Genomeditech/GM-040403
Puromycin Genomeditech/GM-040401
Recombinant Human IL-17A (C-6His) Novoprotein/C774
Recombinant Human IL-17F (C-6His) Novoprotein/CA22
Recombinant Human IL-25 (C-6His) Novoprotein/C792
Anti-IL-17A hIgG1 Antibody(Secukinumab) Genomeditech/GM-27267AB
Anti-IL17RA hIgG2 Antibody(brodalumab) Genomeditech/GM-47619AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit Genomeditech/GM-040513
Reagent Ordering Information
EMEM ATCC/30-2003
Fetal Bovine Serum ExCell/FSP500
Pen/Strep Thermo/15140-122
Blasticidin Genomeditech/GM-040404
Bleomycin Genomeditech/GM-040407
Hygromycin Genomeditech/GM-040403
Puromycin Genomeditech/GM-040401
Recombinant Human IL-17A (C-6His) Novoprotein/C774
Recombinant Human IL-17F (C-6His) Novoprotein/CA22
Recombinant Human IL-25 (C-6His) Novoprotein/C792
Anti-IL-17A hIgG1 Antibody(Secukinumab) Genomeditech/GM-27267AB
Anti-IL17RA hIgG2 Antibody(brodalumab) Genomeditech/GM-47619AB
GMOne-Step 2.0 Luciferase Reporter Gene Assay Kit Genomeditech/GM-040513
Cell Culture

Cell Recovery

Recovery Medium: EMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a)          Remove and discard culture medium.

b)         Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.

c)          Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).

d)         Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

e)          Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.

f)          After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.

g)         Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a)          Upon initial revival, a higher number of dead cells and poor adherence are observed, which is normal. Adherence typically recovers within 2 - 3 days. After 2 - 3 passages, the proportion of adherent cells increases, and the cells begin to spread normally.

b)         After each passage, there may be 5 - 10% dead cells; however, as the number of passages increases, the recovery rate accelerates, the proportion of dead cells decreases, and the cell growth rate stabilizes.

c)          It is recommended to retain cell images after revival and during each observation to assist in assessing cell status. In case of abnormalities, promptly communicate with Genomeditech sales.

Cell Recovery

Recovery Medium: EMEM+10% FBS+1% P.S

To insure the highest level of viability, thaw the vial and initiate the culture as soon as possible upon receipt. If upon arrival, continued storage of the frozen culture is necessary, it should be stored in liquid nitrogen vapor phase and not at -70°C. Storage at -70°C will result in loss of viability.

a)       Thaw the vial by gentle agitation in a 37°C water bath. To reduce the possibility of contamination, keep the O-ring and cap out of the water. Thawing should be rapid (approximately 2 - 3 minutes).

b)       Remove the vial from the water bath as soon as the contents are thawed, and decontaminate by dipping in or spraying with 70% ethanol. All of the operations from this point on should be carried out under strict aseptic conditions.

c)       Transfer the vial contents to a centrifuge tube containing 5.0 mL complete culture medium and spin at approximately 176 x g for 5 minutes. Discard supernatant.

d)       Resuspend cell pellet with the recommended recovery medium. And dispense into appropriate culture dishes.

e)       Incubate the culture at 37°C in a suitable incubator. A 5% CO₂ in air atmosphere is recommended if using the medium described on this product sheet.

Cell Freezing

Freezing Medium: 90% FBS+10% DMSO

a)          Centrifuge at 176 x g for 3 minutes to collect cells.

b)         Resuspend the cells in pre-cooled freezing medium and adjust the cell density to 5E6 cells/mL.

c)          Aliquot 1 mL into each vial.

d)         Place the vial in a controlled-rate freezing container and store at -80°C for at least 1 day, then transfer to liquid nitrogen as soon as possible.

Cell passage

Growth medium: EMEM+10% FBS+1% P.S+3 μg/mL Blasticidin+100 μg/mL Bleomycin+100 μg/mL Hygromycin+1.5 μg/mL Puromycin

For the first 1 to 2 passages post-resuscitation, use the recovery medium. Once the cells have stabilized, switch to a growth medium.

a)          Remove and discard culture medium.

b)         Briefly rinse the cell layer with PBS to remove all traces of serum that contains trypsin inhibitor.

c)          Add 1.0 mL of 0.25% (w/v) Trypsin-EDTA solution to dish and observe cells under an inverted microscope until cell layer is dispersed (usually within 30 to 60 seconds at 37°C).

d)         Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37°C to facilitate dispersal.

e)          Add 2.0 mL of growth medium to mix well and aspirate cells by gently pipetting.

f)          After centrifugation, resuspend the pellet and add appropriate aliquots of the cell suspension to new culture vessels.

g)         Incubate cultures at 37°C.

Subcultivation Ratio: A subcultivation ratio of 1:3 - 1:4 is recommended

Medium Renewal: Every 2 to 3 days

Notes

a)          Upon initial revival, a higher number of dead cells and poor adherence are observed, which is normal. Adherence typically recovers within 2 - 3 days. After 2 - 3 passages, the proportion of adherent cells increases, and the cells begin to spread normally.

b)         After each passage, there may be 5 - 10% dead cells; however, as the number of passages increases, the recovery rate accelerates, the proportion of dead cells decreases, and the cell growth rate stabilizes.

c)          It is recommended to retain cell images after revival and during each observation to assist in assessing cell status. In case of abnormalities, promptly communicate with Genomeditech sales.

Related products
IL-17
H_IL17A Reporter 293 DDX35TM Cell Line Membrane Bound H_IL17A CHO-K1 Cell Line
Anti-IL-17A hIgG1 Antibody(Secukinumab) Anti-IL17A hIgG1 Reference Antibody (Secubio) Anti-IL17A hIgG4 Reference Antibody (Ixebio)
Anti-IL17A×IL17F hIgG1 Bispecific Antibody(Bimebio) Anti-IL17A×IL17F hIgG1 Bispecific Antibody(VH1-1-VL5)
Biotinylated Human IL-17A Protein; His-Avi Tag Biotinylated Human IL-17RA Protein; His-Avi Tag Cynomolgus IL-17A Protein; His Tag
Cynomolgus IL-17F Protein; His Tag Human IL-17A Protein; hFc Tag Human IL-17A Protein; His Tag
Human IL-17E Protein; His Tag Human IL-17F Protein; His Tag  
IL-23
H_IL-23 Reporter 293 Cell Line H_IL-23 Reporter 293 DDX35TM Cell Line Cynomolgus_IL-23R HEK-293 Cell Line
H_IL-23R HEK-293 Cell Line H_IL-23R IL12RB1 HEK-293 Cell Line Membrane bound H_IL-23 CHO-K1 Cell Line
Anti-IL23A hIgG1 Reference Antibody (Gusebio) Anti-IL23A hIgG1 Reference Antibody (Risbio) Anti-IL-23R hIgG1 Antibody(5D4)
Biotinylated Human IL-23A&IL-12B Heterodimer Protein; His-Avi Tag Cynomolgus IL-23A & Human IL-12B Heterodimer Protein; His Tag Cynomolgus IL-23A & Mouse IL-12B Heterodimer Protein; His Tag
Cynomolgus IL-23R Protein; hFc Tag Human IL-23A & Mouse IL-12B Heterodimer Protein; His Tag Human IL-23A&IL-12B Heterodimer Protein; His Tag
Human IL-23R Protein; hFc Tag Human IL-23R Protein; His Tag Mouse IL-23A&IL-12B Heterodimer Protein; His Tag
TNF:TNFR2:TNFR1
H_TNFR2 Null Reporter Cell Line H_TNFR2 Reporter Jurkat Cell Line H_TNFR2 Reporter V2 Cell Line
Cynomolgus_TNFRSF1B(TNFR2) CHO-K1 Cell Line H_TNFRSF1B(TNFR2) CHO-K1 Cell Line H_TNFRSF1B(TNFR2) HEK-293 Cell Line
Membrane Bound H_TNFα CHO-K1 Cell Line Membrane Bound H_TNFα(cleavage-resistant) CHO-K1 Cell Line
Anti-H_TNFRSF1B(TNFR2) hIgG1 Antibody(UC2.3.8) Anti-TNFR1 hIgG1 Antibody(Atrosab) Anti-TNF-α hIgG1 Reference Antibody (Adabio)
Cynomolgus TNFR2 Protein; His Tag Human TNF alpha Protein; hFc Tag Human TNF alpha Protein; His Tag
Human TNFR1 Protein; hFc Tag Human TNFR1 Protein; His Tag Human TNFR2 Protein; hFc Tag
Human TNFR2 Protein; His Tag    
Message consultation
reset
submit
Message
Message consultation
reset
submit